Companies:
50,244
Total Market Cap:
139209015321083.68
Global Rank
#34311
Country Rank
#416
Market Cap
27.43 M
Price
0.38
Change (%)
6.29%
Volume
944,046
Nicox S.A.'s latest marketcap:
27.43 M
As of 08/02/2025, Nicox S.A.'s market capitalization has reached $27.43 M. According to our data, Nicox S.A. is the 34311th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 27.43 M |
| Revenue (ttm) | 4.14 M |
| Net Income (ttm) | -20,108,665.6 |
| Shares Out | 72.2 M |
| EPS (ttm) | -0.42 |
| Forward PE | 5.47 |
| Ex-Dividend Date | n/a |
| Earnings Date | 07/18/2025 |
Market Cap Chart
Data Updated: 08/02/2025
Nicox S.A.'s yearly market capitalization.
Nicox S.A. has seen its market value drop from €184.89 M to €23.68 M since 2014, representing a total decrease of 87.19% and an annual compound decline rate (CAGR) of 17.64%.
| Date | Market Cap(€) | Market Cap(USD) | Change (%) | Global Rank |
|---|---|---|---|---|
| 08/02/2025 | €23.68 M | $27.43 M | 22.56% | 34311 |
| 12/31/2024 | €19.32 M | $20 M | -12.36% | 34156 |
| 12/29/2023 | €22.05 M | $24.33 M | -60.51% | 32533 |
| 12/30/2022 | €55.83 M | $59.75 M | -49.18% | 25685 |
| 12/31/2021 | €109.84 M | $124.85 M | -31.81% | 21674 |
| 12/31/2020 | €161.08 M | $196.74 M | 11.31% | 16857 |
| 12/31/2019 | €144.72 M | $162.27 M | -2.8% | 15717 |
| 12/31/2018 | €148.89 M | $170.72 M | -50.16% | 14681 |
| 12/29/2017 | €298.72 M | $358.28 M | 40.32% | 12057 |
| 12/30/2016 | €212.88 M | $223.86 M | 2.02% | 12348 |
Company Profile
About Nicox S.A.
Nicox S.A., together with its subsidiaries, operates as an ophthalmology company in France and internationally. Founded in 1996 and headquartered in Biot, France, the company focuses on developing innovative solutions to maintain vision and improve ocular health.
Key Product Candidates
- NCX 470 – A novel nitric oxide (NO)-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Currently in Phase 3 clinical trial.
- NCX 4251 – A patented ophthalmic suspension of fluticasone propionate nanocrystals for treating dry eye disease. Currently in Phase 2b clinical trial.
- NCX 1728 – An NO-donating phosphodiesterase-5 inhibitor in preclinical evaluation.
Commercialized Products
- VYZULTA – A latanoprostene bunod ophthalmic solution for treating open-angle glaucoma or ocular hypertension.
- ZERVIATE – A cetirizine ophthalmic solution for managing ocular symptoms associated with allergic conjunctivitis.
Frequently Asked Questions
-
What is Nicox S.A.'s (EPA-ALCOX) current market cap?As of 08/02/2025, Nicox S.A. (including the parent company, if applicable) has an estimated market capitalization of $27.43 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Nicox S.A. (EPA-ALCOX) rank globally by market cap?Nicox S.A. global market capitalization ranking is approximately 34311 as of 08/02/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.